| Source: |
| Type: |
| Selenoproteins are a group of proteins that incorporate the rare amino acid selenocysteine into their structure. Selenocysteine, sometimes called the “21st amino acid,” is encoded by the UGA codon in a unique context that requires specific translational machinery. Many selenoproteins are known for their antioxidant and redox-regulatory functions, which are critical in maintaining cellular homeostasis. These functions help protect cells from oxidative stress and damage—processes that, when dysregulated, can contribute to carcinogenesis. Roles of Selenoproteins in Cancer. 1. Antioxidant Defense & Redox Regulation -Glutathione Peroxidases (GPxs): Enzymes like GPX1, GPX2, and GPX3 reduce hydrogen peroxide and lipid hydroperoxides. This protects cells against oxidative DNA damage. -Thioredoxin Reductases (TXNRDs): TXNRD1, TXNRD2, and TXNRD3 help maintain the reduced state of thioredoxin, thereby contributing to redox homeostasis and cell survival under stress. 2. Cellular Proliferation and Apoptosis -Selenoproteins may modulate signaling pathways that regulate cell cycle progression and apoptosis. Variations in expression levels—either upregulation or downregulation—can tip the balance toward uncontrolled cell growth or cell death. The expression of selenoproteins in cancers is complex and can vary by tumor type. Here are some examples: Glutathione Peroxidases (GPxs) -GPX1: Both overexpression and underexpression have been reported depending on the tumor context. In some cases, high GPX1 expression can help cancer cells survive oxidative stress. -GPX2: Often upregulated in colorectal cancer and some GC, poor prognosis. -GPX3: Typically downregulated in many cancers with tumor progression and poor outcome, suggesting its role as a tumor suppressor. Thioredoxin Reductases (TXNRDs) -TXNRD1: Frequently overexpressed in various tumors such as lung, breast, and liver cancers. High TXNRD1 levels are generally associated with a poor prognosis. -SELENOP (Selenoprotein P) SELENOP serves as a selenium transport protein and has antioxidant properties. Decreased SELENOP expression has been linked to poorer outcomes in some cancers, possibly due to reduced selenium availability for other protective selenoproteins. Other Selenoproteins -SELENOF and SELENOS: -SELENOM and SELENOK: |
| 1694- | Se, | Expression of Selenoprotein Genes and Association with Selenium Status in Colorectal Adenoma and Colorectal Cancer |
| - | Analysis, | CRC, | NA |
| 4608- | Se, | Selenium Nanoparticles for Biomedical Applications: From Development and Characterization to Therapeutics |
| - | Review, | Var, | NA | - | NA, | AD, | NA |
| 4614- | Se, | Rad, | Updates on clinical studies of selenium supplementation in radiotherapy |
| - | Review, | Nor, | NA |
| 4613- | Se, | Rad, | Effect of Selenium and Selenoproteins on Radiation Resistance |
| - | Review, | Nor, | NA |
| 4610- | Se, | Rad, | Protection during radiotherapy: selenium |
| - | Review, | Var, | NA |
| 4605- | Se, | Selenium nanoparticles: An insight on its Pro-oxidant andantioxidant properties |
| - | Review, | NA, | NA |
| 4609- | Se, | Physiological Benefits of Novel Selenium Delivery via Nanoparticles |
| - | Review, | Var, | NA | - | Review, | IBD, | NA | - | Review, | Diabetic, | NA |
| 4724- | Se, | Chapter Four - Selenium in the Redox Regulation of the Nrf2 and the Wnt Pathway |
| - | Review, | Var, | NA |
| 4721- | Se, | A review on selenium nanoparticles and their biomedical applications |
| - | Review, | AD, | NA | - | Review, | Diabetic, | NA | - | Review, | Arthritis, | NA |
| - | in-vivo, | Var, | NA |
| 4717- | Se, | A systematic review of Selenium as a complementary treatment in cancer patients |
| - | Review, | Var, | NA |
| 4712- | Se, | Selenium and selenoproteins: key regulators of ferroptosis and therapeutic targets in cancer |
| - | Review, | Var, | NA |
| 4740- | Se, | Optimising Selenium for Modulation of Cancer Treatments |
| - | Review, | Var, | NA |
| 4739- | Se, | Chemo, | Rad, | Therapeutic Benefits of Selenium in Hematological Malignancies |
| - | Review, | Var, | NA |
| 4733- | Se, | Selenium supplementation of lung epithelial cells enhances nuclear factor E2-related factor 2 (Nrf2) activation following thioredoxin reductase inhibition |
| - | NA, | Nor, | NA |
| 4494- | Se, | Advances in the study of selenium and human intestinal bacteria |
| - | Review, | IBD, | NA | - | Review, | Var, | NA |
| 4497- | Se, | Selenium and inflammatory bowel disease |
| - | Review, | Var, | NA | - | Review, | IBD, | NA |
| 4498- | Se, | Selenium in Human Health and Gut Microflora: Bioavailability of Selenocompounds and Relationship With Diseases |
| - | Review, | Var, | NA | - | Review, | AD, | NA | - | Review, | IBD, | NA |
| 4503- | Se, | Prophylactic supplementation with biogenic selenium nanoparticles mitigated intestinal barrier oxidative damage through suppressing epithelial-immune crosstalk with gut-on-a-chip |
| - | in-vitro, | Nor, | NA |
| 4441- | Se, | The Role of Selenium Nanoparticles in the Treatment of Liver Pathologies of Various Natures |
| - | Review, | Nor, | NA |
| 4492- | Se, | Selenium in cancer prevention: a review of the evidence and mechanism of action |
| - | Review, | Var, | NA |
| 4457- | Se, | Selenium nanoparticles: a review on synthesis and biomedical applications |
| - | Review, | Var, | NA | - | NA, | Diabetic, | NA |
| 4491- | Se, | Chit, | VitC, | Synthesis of a Bioactive Composition of Chitosan–Selenium Nanoparticles |
| - | Study, | NA, | NA |
| 4485- | Se, | Selenium stimulates the antitumour immunity: Insights to future research |
| - | Review, | NA, | NA |
| 1908- | SNP, | Exposure to Silver Nanoparticles Inhibits Selenoprotein Synthesis and the Activity of Thioredoxin Reductase |
| - | in-vitro, | Lung, | A549 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:1172 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid